Similar Items

Cover Image

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Aims. Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) lowering treatment in the overall group, but a reduction in events in the thir...

Full description

Saved in:
Bibliographic Details
Institution:Universidad EIA
Main Authors: Bosch, Jackie, Lonn, Eva M., Jung, Hyejung, Zhu, Jun, Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Xavier, Denis, Diaz, Rafael, Dagenais, Gilles, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Kati, Keltai, Matya, Sliwa, Karen, Held, Claus, Peters, Ronald J.G., Lewis, Basil S., Jansky, Petr, Yusoff, Khalid, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Joseph, Philip, Leiter, Lawrence A., Yusuf, Salim, The Heart Outcomes Prevention Evaluation (HOPE)-3 Investigators, Masira
Format: Artículo de revista
Language:English
Published: Oxford Academic 2021-08-14
Subjects:
Primary prevention
Cardiovascular disease
Statins
Online Access:https://repositorio.udes.edu.co/handle/001/6117
Tags: Add Tag
No Tags, Be the first to tag this record!